H.C. Wainwright Global Investment Conference September 6, 2018 OTC: PRED predtechgroup.com
|
|
- Arnold Harrell
- 5 years ago
- Views:
Transcription
1 H.C. Wainwright Global Investment Conference September 6, 2018 OTC: PRED predtechgroup.com
2 Safe Harbor This presentation contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," or the negative of such terms or other similar expressions. The Company cautions readers not to place undue reliance on any forward-looking statements which speak only as of the date made, are based on certain assumptions and expectations which may or may not be valid or actually occur, and which involve various risks and uncertainties, including but not limited to risk of market acceptance; economic conditions, unanticipated operating costs, new market entrants, changes in technology, ability to develop strategic relationships, ability to hire and retain necessary personnel, adequate of financial resources, health care reform, changes in government regulation, ability to obtain adequate reimbursement from insurers, ability to protect intellectual property, ability to obtain tissue from human donors that is necessary for our HCT/P products, conduct of lab operations, meeting FDA requirements, thinly traded market for our securities, ability to obtain or maintain listing on NASDAQ or an exchange, lack of operating history and other risks. Actual results may differ materially from those set forth in this presentation due to such risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. 1
3 Vision Statement Improving lives through data analytics, diagnostics and precision biopharmaceutical solutions. 2
4 Company Overview Operates Three Subsidiaries Develops and commercializes novel genetic-based diagnostics and therapeutics Initial focus is on endometriosis and fertility, with pipeline programs in women s health and spinerelated disorders Genetic-based diagnostics allow precision medicine/therapeutics at earliest possible point of intervention Develops and commercializes regenerative human tissue, human cell and cellular products Core competency in cell and tissue processing Through fully integrated CLIAcertified, CAP-accredited and AATB registered laboratory Four commercialized products Secures procurement of tissue for Predictive Biotech products Biorepository of DNA, postpartum placental cells and tissue and related health care records Cell and tissue source for autologous and allogeneic products Research and development Making cell and tissue banking affordable to all mothers 3
5 Predictive Technology Group Management Team Name Bradley Robinson In Process Tim Lacy Paul Evans Michael Herbert John Nelson, M.D. Mike Dey, Ph.D. Eric Olson Title Chief Executive Officer Chief Financial Officer Chief Revenue Officer Chief Operations Officer Chief Marketing Officer Chief Medical Officer CEO Predictive Therapeutics CEO Predictive Biotech 4
6 Predictive Technology Group Advisory Board Name Ronald Barhorst Hugh S. Taylor, M.D. Nick M. Spirtos, M.D. John Sorrentino Jonas Cedergren Ken Ward, M.D. 5 Title ING Financial - CEO (retired 2014) Yale School of Medicine New Haven Hospital - Professor and Chair, Department of Obstetrics, Gynecology and Reproductive Sciences. Medical Director Women s Cancer Center of Nevada Pfizer - COO, Pediatrics, Vaccines, R&D Managing Director - JC Capital Advisors Juneau Biosciences - CEO
7 Investment Highlights Proven management team with success from R&D, to operations and commercialization First product line - internally developed Human Cell and Tissue Products - launched in 2017 with ongoing, strong revenue growth that has established PRED as the industry leader Expect to launch 2 novel, genetic-based endometriosis and fertility diagnostic/prognostic tests in late 2018 Broad, follow-on pipeline of diagnostics and therapeutics in the near-, mid-, and longterm, including: Novel endometriosis therapeutic to treat and suppress/delay disease progressions with clear regulatory path in this large, underserved market Pipeline of genetic-based diagnostics for hard-to-diagnose women s health and spinal disorders Cash positive operating position with no debt (only operating payables) Pursuing a near-term NASDAQ listing 6
8 Growth Drivers Continued expansion of existing human cell and tissue lines Allograft sales in 2017 exceed 10,000 and 2018 YTD exceed 20,000 2X 2017 allograft sales in first eight months of ,000 allografts used in human patients de-risk product development as allograft results predict outcomes of FDA clinical studies Allograft sales and patient data accelerate and de-risk product development and reduce clinical trial timelines Near-, mid- and long-term proprietary product and technology platforms, driven by significant, proprietary R&D assets and strong intellectual property positions Proven national sales infrastructure with ability to commercialize new products and expand into complementary sectors 7
9 Advanced regenerative medicine products that enhance the body s natural ability to heal and augment current therapies
10 2018 Strong Revenue Growth - Cell and Tissue Products 2017 and 2018 Sales Actual vs Forecast Year end: June 30 $3,000,000 $2,500,000 $2,000, FY Q1 Q2 Q3 Q4 FY Actual $2.2 $3.2 $4.2 $7.2 $16.8 Forecast $1.2 $2.0 $3.2 $4.0 $10.4 Exceeded $1.0 $1.2 $1.0 $3.2 $6.4 Revenue growth continues to accelerate Every quarter to date exceeded forecast CAGR 153.6% (Since 2017) Margins continue to improve $1,500,000 $1,000,000 $500,000 9 $- Jan Feb Mar Apr May June July Aug Sept Oct Nov Dec Jan Feb Mar April May June Forecast Actual
11 Overview Predictive Biotech was established to: Provide advanced regenerative medicine products Enhance the body s natural ability to heal Augment and co-administration to current therapies Develop cell and tissue processing platform What is Regenerative Medicine? Regenerative medicine is quickly emerging as a therapeutic disrupter across a wide spectrum of diseases and becoming an accepted therapeutic for how certain human ailments are managed and treated Allogeneic human cell and tissue products are able to supplement the body s natural healing process. 10
12 How does Regenerative Medicine Work? As our bodies age, we experience: Longer healing times Increased inflammation Changing chemical environment Cell exhaustion (cell aging) Building Blocks: Over time, healthy tissue can become dysfunctional due to age and injury. A human cell and tissue product (HCT/P) is administered to a recipient to repair, reconstruct, replace, or supplement the same basic functions of the recipient s cells or tissues The human body utilizes a variety of tissue and cell interactions to support the healing process. Predictive s human cell and tissue allografts supplement similar tissue in your body via scaffolding, growth factor, homeostatic and general cytokines 11
13 Product Portfolio 12
14 Procurement and Process 13
15 Improving lives through data analytics, diagnostics and precision biopharmaceutical solutions.
16 Research and Development Platform Assets Library of 300,000 DNA samples with genetic birth defect or serious maternity issue HIPAA compliant Collected from most genetically diverse population in the U.S. Believed to be the world s largest DNA library related to women s health Proprietary genealogy database used to accelerate genetic discoveries Corresponding proprietary genealogy database developed from >50,000 public sources Approximately 36 million names in the database 15
17 What is Endometriosis? A painful disorder in which tissue that normally lines the inside the uterus the endometrium grows outside the uterus. Affects 1 in 10 women during their reproductive years * 27 million symptomatic women in U.S. 176 million women worldwide 30-50% of women with endometriosis may experience fertility issues ** One of the leading causes of female infertility** No effective non-surgical method to diagnose No therapeutic cure *Macer, et. al, Endometriosis and Infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility Obstet Gynecol Clin Dec **We describe a range because the incidence depends on method used to look for endometriosis, age and characteristics of the infertility patient cohort: i. "The incidence of endometriosis among infertile women is between 30% and 45%, and has been as high as 68% in centers with laparoscopists who are proficient at finding subtle endometriosis." Marian D. Damewood, Pathophysiology and Management of Endometriosis, Journal of Family Practice (July 1993). ii. It has been reported that 20-68% of women with endometriosis have some degree of infertility. Marcoux et. al, New England Journal of Medicine, 337:4 Laparoscopic Surgery in Infertile Women with Minimal or Mild Endometriosis (1997). iii. "Early studies suggested that 25% to 50% of infertile women have endometriosis and that 30% to 50% of women with endometriosis are infertile." Fertility and Sterility Vol. 86, Suppl 4, November
18 Problem #1: Endometriosis Underlying Infertility 25-50% of infertile women have endometriosis* IVF complications are greater in women with active endometriosis Increased risk of adverse pregnancy outcomes in women with endometriosis Evidence-based diagnosis for endometriosis was accompanied by significant drop in IVF success rates ** No reliable laboratory test or surgical diagnosis * Bulletti, et al; Endometriosis and Infertility J Assist Reprod Genet, August 2010 **Molinaro, et al; Fertil Steril 2009;92: by American Society for Reproductive Medicine 17
19 Solution: Suite of Endometriosis and Infertility Tests Diagnostic Test ARTGuide Non-invasive diagnostic test for endometriosis and other genetic causes of infertility. Indicated for the 1 in 8 women with infertility and leads to better decision making regarding IVF and other treatments Fertility Dx ARTGuide plus expanded carrier screening plus chromosomal microarray most comprehensive test panel for genetic abnormalities ENDORisk Identifies patient s risk for endometriosis in women with symptoms CLIA-validated LDT test with no required FDA approvals 18
20 ARTGuide : Test Development Endometriosis R&D based on: >30,000 endometriosis patients >100,000 sequenced population controls Validation Comprehensive 2 phase GWAS discovery 3,000 exomes sequenced to detect low frequency variants >1,000 useful markers patented Independent training cohort, 3 different test validation cohorts 19
21 ARTGuide Test 3 classes of markers SNP (70 SNPs) SNP (1,300 mutations) Sequencing (10 genes) Integrating genetic risk with clinical criteria achieves >90% Area Under Receiver Operator Characteristic Curve (ROC) >1,400 endometriosis markers Human genes 4 clinical questions Strong positive and negative predictive values Cost of goods to assay all markers is less than $100 per sample Run on Next Gen Sequencer 20
22 ARTGuide & Fertility Dx Commercialization First Products to Market Efficient sales to large, yet highly concentrated market 480 assisted reproduction technology (ART) clinics in the U.S.; 80% of market in 6 metro regions Self-pay test with no reliance on reimbursement 8-10 sales representatives can cover ART market Market research based on survey of 20 infertility specialists All expressed interest, 1/3 would offer test to 100% of new patients Survey indicates average of 35 prescriptions / month / doctor Initial targets are 15 larger clinics for clinical research / KOL development Assuming conversion of 12 clinics, each with 9 doctors, produces >$150 million in annual revenues 21
23 Problem #2: Endometriosis and Chronic Pain Abnormal tumors cause bleeding, scarring and inflammation Endometriosis can cause chronic, debilitating pelvic pain No reliable laboratory test Healthcare costs are 63% higher for affected women Patients miss an average of one week each month from work Annual economic costs exceed $85 billion, e.g., two-thirds is associated with lost productivity, and one-third direct health care costs 86.5% of women with endometriosis presented depressive symptoms To be honest, ENDO ruins my life it robs me of days each month I am at my wits end with this disease. It always wins and I am fighting a war against Endo in my body. - Juneau Biosciences Research Participant Human Reproduction, Volume 27, Issue 5, 1 May 2012, Pages Fertil Steril 2011 Aug;96(2): e8 Eur J Obstet Gynecol Reprod Biol Jan;142(1):
24 Solution: ENDORisk and NHP-07 Therapeutic Diagnostic - ENDORisk Predictive genetic test for endometriosis covered by key issued and pending patents Incorporates proprietary endometriosis, pain and inflammation markers with high predictive value based on patented DNA markers Therapeutic NHP-07 Proprietary therapeutic for endometriosis prevention and/or suppression Can be administered prior to disease development or after exhibiting initial symptoms to suppress/delay disease progression Clear regulatory path with combination of FDA approved compounds 23
25 Competitive Landscape No competitors for predictive DNA endometriosis test Small company has developed CNV markers Immunologic, protein, gene expression, mirna test, endometrial biopsy, CT scan tests under development Accelerating pharma interest in endometriosis AbbVie received FDA approval for Orilissa on June 24, 2018 Myovant $218 million IPO in October 2016 (now $1.5 billion market cap) developing candidate Relugolix ENDORisk is a potential companion diagnostic for each of these market participants 24
26 Product Pipeline in Spine Disorders Current diagnostic methods are invasive and expensive Need for diagnostic to determine course of care for better outcomes Need for payers to better determine the risk of the insured population Scoliosis Diagnostic Test Proprietary genetic-based test predicts disease progression Degenerative Disc Disease Diagnostic Test Proprietary genetic-based test predicts disease progression 25
27 Quarterly Financials 8,000,000 7,000,000 7,161,157 7,016,989 6,000,000 5,000,000 3,889,656 4,000,000 1,885,443 3,000,000 2,000,000 1,417,582 1,000, ,000,000 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 (596,232) -2,000,000 Total Income Gross Profit EBITDA Linear (Total Income) Linear (Gross Profit) Linear (EBITDA) 26
28 Predictive Consolidated Financial Highlights in 000s FYE FYE Change FYE FYE Change Revenue $ 16,624 $ 2, % $ 2,585 $ % GP % 76.1% 70.9% 7.3% 70.9% 0.0% 100.0% R&D % 11.4% 3.3% 245.5% 3.3% 1.3% 153.8% Sales % % 30.2% 6.3% 30.2% 9.0% 235.6% G&A % % 32.5% (32.3)% 32.5% 1,843.3% (98.2)% Net Inc. (12,097) (6,205) 95.0% (6,205) (16,629) (62.7)% Adj NI 2 (1,940) (3,673) (47.2)% (3,673) (1,101) 233.6% Adj EBITDA 2 2, ,471.4% 21 (108) (119.4)% Cash from Ops (350) 918 (138.1)% 918 (141) (751.1)% June 30 Fiscal Year End For further detail see audited financials (1) Excludes non-cash compensation (2) Non-GAAP measurement (3) June 30 fiscal year end 27
29 In Summary Proven management team with success from R&D, to operations and commercialization First product line - internally developed Human Cell and Tissue Products - launched in 2017 with ongoing, strong revenue growth that has established PRED as the industry leader Expect to launch 2 novel, genetic-based endometriosis and fertility diagnostic/prognostic tests in late 2018 Broad, follow-on pipeline of diagnostics and therapeutics in the near-, mid-, and longterm, including: Novel endometriosis therapeutic to treat and suppress/delay disease progressions with clear regulatory path in this large, underserved market Pipeline of genetic-based diagnostics for hard-to-diagnose women s health and spinal disorders Cash positive operating position with no debt (only operating payables) Pursuing a near-term NASDAQ listing 28
LD Micro Invitational June 4, 2018 OTC: PRED predtechgroup.com
LD Micro Invitational June 4, 2018 OTC: PRED predtechgroup.com Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
More informationDecember 4, 2018 OTC: PRED predtechgroup.com
December 4, 2018 OTC: PRED predtechgroup.com Safe Harbor This presentation contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationCorporate Presentation. First Quarter 2018
Corporate Presentation First Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationNASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationMedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy
MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationA Rare Opportunity in Transplant.
A Rare Opportunity in Transplant. ENV-18-104.0 1 Forward Looking Statements Certain information in this presentation may constitute forward-looking information within the meaning of applicable securities
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationJefferies Global Life Sciences Conference June 2010
Jefferies Global Life Sciences Conference June 2010 Cautionary Statement This presentation contains "forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More information- Linzagolix overall efficacy and safety maintained or improved at week 24
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain - Linzagolix overall efficacy
More informationASX Announcement 22 June 2017
ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationMAKO Surgical Corp. January MAKO Surgical Corp
MAKO Surgical Corp. January 2012 MAKO Surgical Corp. 2012 1 Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, statements related to expectations,
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationAgreement to Acquire Spinal Kinetics, Inc. March 15, 2018
Agreement to Acquire Spinal Kinetics, Inc. 1 March 15, 2018 2 SAFE HARBOR STATEMENT AND USE OF NON GAAP MEASURES WHY SPINAL KINETICS? The Spinal Kinetics M6 artificial discs further round out Orthofix
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationMedifocus, Inc. OTCQX: MDFZF TSXV: MFS
Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Develops and commercializes minimally invasive focused heat thermotherapy systems for the treatment of cancer and other diseases January 2014
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationDiagnostics for the early detection and prevention of colorectal cancer.
Diagnostics for the early detection and prevention of colorectal cancer. Company Presentation May 2013 Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements
More informationThe New England Journal of Medicine. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer
The New England Journal of Medicine A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer May 18, 2015 Forward-Looking Statements Various remarks that we make on this call that are
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationThird Quarter Results to September 30, 2009
Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More information21 st Annual Needham Growth Conference
21 st Annual Needham Growth Conference Title January 15, 2019 Bonnie Anderson Chairman and Chief Executive Officer Forward-Looking Statements This presentation contains forward-looking statements, within
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationCompany Presentation. Nasdaq: MDWD. June Gal Cohen, President & CEO
Company Presentation June 2015 Nasdaq: MDWD Gal Cohen, President & CEO Cautionary note Regarding Forward-looking statements This presentation contains forward-looking statements within the meaning of Section
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationNovember 2016 NASDAQ: ATRS
November 2016 NASDAQ: ATRS Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of
More information